Introduction: The 2-[18F]-Fluorodeoxyglucose (FDG) positron emission tomography (PET/CT) has become an imaging tool for clinical assessment of tumor, node, metastasis in non–small-cell lung cancer (NSCLC). Primary tumor maximum standardized uptake value (SUVmax) on 18F-FDG PET/CT before and after radiation therapy (RT) has been studied as a potential prognostic factor for NSCLC patients receiving radiotherapy. However, the sample sizes of most studies were small, and the results of the prediction value of SUVmax remained undetermined, which lead us to perform a meta-analysis to improve the precision in estimating its effect.

Methods: We performed a meta-analysis of published literature for primary tumor SUVmax-based biomarkers of the outcome of NSCLC receiving radiotherapy. The required data for estimation of individual hazard ratios (HRs) to compare patients with a low and a high SUVmax were extracted from each publication. A combined HR was calculated by Stata statistical software (Version 11). All of the results were verified by two persons to ensure its accuracy.

Results: Thirteen studies were finally included into this meta-analysis; data are available in 13 studies for pre-RT primary tumor SUVmax and in five studies for post-RT. For overall survival, the combined HR estimate was 1.05 (95% confidence interval [CI], 1.02–1.08) and 1.32 (95% CI, 1.15–1.51) for pre-RT SUVmax and post-RT SUVmax, respectively; 1.26 (95% CI, 1.05–1.52) and 2.01 (95% CI, 1.16–3.46) for local control (LC). In stereotactic body radiotherapy (SBRT) group, HR for LC was 1.11 (95% CI, 1.06–1.18) and 2.19 (95% CI, 1.34–3.60) for pre-SBRT SUVmax and post-SBRT SUVmax, respectively.

Conclusion: Both pre-RT and post-RT primary tumor SUVmax can predict the outcome of patients with NSCLC treated with radiotherapy. Patients with high levels of pre-RT SUVmax seemed to have poorer overall survival and LC.

Key Words: Primary tumor maximum standardized uptake value, Prognosis, Non–small-cell lung cancer, Meta-analysis, Radiotherapy.

Lung cancer is the leading cause of cancer-related death worldwide.1 Non–small-cell lung cancer (NSCLC) accounts for 85% of all lung cancers. NSCLC is often treated with a combination of multiple types of therapies, including radiation therapy (RT). The dose limitation and therefore therapeutic efficacy of RT have been addressed by recent progresses, including stereotactic body radiotherapy (SBRT) and image-guided and intensity-modulated radiotherapy.2 For inoperable patients with early stage NSCLC, SBRT presents as a new standard treatment. Despite these improvements, the 5-year survival rate is generally approximately 15%,3 and somewhat higher at 17% to 47%4 in patients with early stage NSCLC.

Information about reliable prognostic factors for RT responses (and prognosis in general) is essential in identifying subjects suitable for aggressive RT treatment. The most commonly used factor for predicting RT responses is the tumor-node-metastasis (TNM) stage.5 Weight loss,6 performance status,6 and molecular markers7,8 were reported to predict the outcome and could be used to stratify patients for the most optimal strategy for RT but require further validation.9 Morphologic changes as reflected by computed tomography (CT) have also been identified as prognostic factors, but technical issues remain (e.g., it is also difficult to differentiate residual tumor from necrosis or fibrosis).10,11 A variety of imaging methods has been developed to examine tumor metabolism.12–14 For example,
18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT is becoming the standard practice for staging and is widely used in post-treatment evaluation of various types of cancer, including breast cancer, lymphoma, head and neck cancer, and NSCLC.15–18 For NSCLC, 18F-FDG PET/CT has been found useful for diagnosing, restaging at recurrence,19 delineating radiotherapeutic targets,20 and evaluating radiotherapeutic or chemotherapeutic effects.19–21 Maximum standardized uptake value (SUV\text{max}) derived from 18F-FDG PET/CT has been reported by some,22–24 but not all,25,26 to predict the responses to RT in patients with NSCLC.

In the current study, we systematically reviewed available information of all published studies of primary tumor SUV\text{max} of NSCLC. Potential prognostic value of primary tumor SUV\text{max} in predicting RT responses was examined using meta-analysis.

**MATERIALS AND METHODS**

**Search Strategy and Eligible Criteria**

The PubMed database was searched (updated on April 3, 2013) used the following terms: (non–small cell lung cancer OR NSCLC) AND (PET imaging tomography OR positron emission tomography OR PET OR 18F-FDG OR fluorodeoxyglucose) AND (prognostic OR survival OR prognostic factor OR outcome OR predict) AND (“radiotherapy”[Mesh] OR radiotherapy OR irradiation). References cited by the articles identified in the electronic search were also reviewed. Conference Abstracts were not included in the search because of a lack of meta-analysis. When the same patient population was reported in more than one article, only the most recent or complete report was included in the final analysis.

This meta-analysis was limited to the studies on prognostic implications (for either overall survival [OS] or local control [LC]) of primary tumor SUV\text{max}, as examined using 18F-FDG PET/CT, in NSCLC patients receiving RT. Case studies and review articles were not included. Studies using prognostic indexes other than OS or LC were also not included.

**Data Extraction**

Information was independently extracted by two investigators (FFN and CL), and it included authors, publication year, source of patients, sample size, main primary tumor SUV\text{max} characteristics, tumor stage, treatment strategy, and survival information (Table 1). OS was defined as the period from the date of enrollment to the date of death. LC was defined as the time between diagnosis and the first local-regional failure.

**Study Quality Control**

The Newcastle–Ottawa Quality Assessment Scale27 was used to assess the methodological quality of the meta-analysis; each study was reviewed by two independent reviewers (FFN and CL). A “star system” is used to obtain the score. Briefly, each study was judged on three broad perspectives: the selection of the study groups, the comparability of the groups, and the ascertainment of either the exposure or outcome of interest. The number of total stars was used to reflect the quality of the included studies. The evaluation was performed by two investigators independently (FFN and CL).

**Statistical Analysis**

Stata statistical software Version 11.0 software (Stata Corporation, College Station, TX) was used to perform this meta-analysis. For OS and LC, hazard ratios (HRs) with 95% confidence interval (95% CI) were calculated. The inter-study heterogeneity was evaluated with the Cochrane’s Q test (\(\alpha = 0.05\)) as well as \(I^2\),28 A fixed effects model (Mantel–Haenszel method) was used to analyze the data as to whether there was no significant heterogeneity; otherwise, a random effects model was used according to the DerSimonian–Laird method.29 Publishing bias was tested with the Begg’s and Egger’s bias indicator test.

HR and 95% CI were directly extracted from the studies that used a multivariate survival analysis32,33,30–35 or univariate analysis.25,26,16,37 If the HR was not given explicitly,24 p value and total events were used to calculate the HR based on a method reported by Tierney et al.38 The final combination of HR was the effect value to show the prognostic significance.

A sensitivity analysis was performed by including only studies of the highest quality (with seven or more stars) or with similar cutoffs.

**RESULTS**

**Study Identification and Quality**

The literature search identified 234 relevant studies, among which 170 studies were eliminated from further analysis by the screening based on title/abstract review and supplemental author searches. The full texts of the remaining 64 articles were retrieved. Careful review of the full text eliminated 51 articles because of a lack of sufficient data (Fig. 1). The final analysis included 13 articles, and, according to the sequence of 18F-FDG PET/CT and RT performing, they were divided into two groups: pre-RT primary tumor SUV\text{max} and post-RT primary tumor SUV\text{max}. Five of the 13 studies had available data for both pre-RT SUV\text{max} and post-RT SUV\text{max}; the remaining eight studies only had pre-RT SUV\text{max} data. The quality of the included studies is shown in Table 1. The quality score ranged from 6 to 8 with a median of 7.38; all 13 studies satisfied most of the items and reported all of the assay method and confounders. Assessment of outcome was the worst described item.

**Characteristics of the Included Studies**

The basic characteristics of the included studies are summarized in Table 1. Studies are listed twice if they provided survival data for both pre-RT and post-RT. All the studies were published during a period from 2005 to 2013. The sample size ranged from 46 to 132.

All 13 studies reported pre-RT SUV\text{max}. In the eight studies (657 patients) that reported OS, three claimed significant positive predict value of OS for RT. In the seven studies (530 patients) that reported LC, three claimed predict effect of LC for RT.
| First Author | Year | Treatment | No. of Patients | Technique | Type of SUV | Correction of SUV | SUV Threshold | Stages | OS/LC | HR Estimate | 95% CIs | Study Quality/Stars |
|--------------|------|-----------|----------------|-----------|-------------|------------------|--------------|--------|------|-------------|--------|------------------|
| Pretreatment |      |           |                |           |             |                  |              |        |     |             |        |                  |
| Clarke22     | 2012 | SBRT (50–60 Gy) | 82          | F18-FDG PET/CT | SUV<sub>max</sub> | Body weight        | 5            | T1-2N0M0 | LC:U+M | HR 1.11     | 1–1.12 | 7                |
| Takeda23     | 2011 | SBRT (40–50 Gy)  | 97          | F18-FDG PET/CT | SUV<sub>max</sub> | Body weight        | 6            | T1-4N0M0 | LC:U+M | HR 2.688    | 1.417–5.1 | 7                |
| Sasaki24     | 2005 | CRT (55–66 Gy)  | 69          | F18-FDG PET/CT | SUV<sub>max</sub> | Body weight        | 5            | Stage I–III | LC:U | events 6.66  | 2.56–16.66 | 7                |
| Lopez Guerra25 | 2012 | CRT (66 Gy)    | 49          | F18-FDG PET/CT | SUV<sub>max</sub> | NR               | 14           | Stage III | LC:U | HR 1.01     | 0.92–1.11 | 7                |
| Zhang26      | 2011 | SBRT (50 Gy)   | 68          | F18-FDG PET/CT | SUV<sub>max</sub> | Body weight        | 5            | Stage I  | LC:U | HR 6.5      | 0.5–32.6 | 7                |
| Zhang26      | 2011 | SBRT (50 Gy)   | 60          | F18-FDG PET/CT | SUV<sub>max</sub> | Body weight        | 5            | NR       | LC:U | HR 5.8      | 0.4–28.9 | 6                |
| Satoh19      | 2011 | SBRT (48–72 Gy) | 57          | F18-FDG PET/CT | SUV<sub>max</sub> | Body weight        | NR           | Stage I  | LC:U+M | HR 1.129    | 0.973–1.311 | 7                |
| Lee31        | 2013 | SBRT (45–60 Gy) | 48          | F18-FDG PET/CT | SUV<sub>max</sub> | Body weight        | 6.8          | T1-2AN0M0 | LC:U+M | HR 4.48     | 0.427–42.91 | 7                |
| Zhang22      | 2010 | CRT (60–65 Gy)  | 46          | F18-FDG PET/CT | SUV<sub>max</sub> | Body weight        | 9.8          | Stage III | OS:U+M | HR 10.56    | 8.76–12.36 | 6                |
| Yan33        | 2011 | CRT           | 120         | F18-FDG PET/CT | SUV<sub>max</sub> | Body weight        | 13           | Stage III–IV | OS:U+M | HR 1.041    | 0.962–1.078 | 6                |
| Chang24      | 2012 | SBRT (50 Gy)   | 130         | F18-FDG PET/CT | SUV<sub>max</sub> | NR               | 6.2          | Stage I  | OS:U+M | HR 2.15     | 1.06–4.34 | 7                |
| Borst35      | 2005 | CRT (77 Gy)    | 51          | F18-FDG PET/CT | SUV<sub>max</sub> | Body weight        | 15           | Stage I–III | OS:U+M | HR 1.06     | 1.02–1.1  | 7                |
| Vikram Rao36 | 2012 | SBRT (60 Gy)   | 132         | F18-FDG PET/CT | SUV<sub>max</sub> | Body weight        | 5            | Stage I  | OS:U+M | HR 4.4      | 0.5–35   | 7                |
| Burdick37    | 2010 | SBRT (50–60 Gy) | 72          | F18-FDG PET/CT | SUV<sub>max</sub> | Body weight        | 5            | T1-2N0M0 | OS:U | HR 1.32     | 0.587–2.99 | 8                |
| Post-treatment |      |           |                |           |             |                  |              |        |     |             |        |                  |
| Clarke22     | 2012 | SBRT (50–60 Gy) | 82          | F18-FDG PET/CT | SUV<sub>max</sub> | Body weight        | 5            | T1-2N0M0 | LC:U+M | HR 1.68     | 0.92–3.06 | 7                |
| Lopez Guerra25 | 2012 | CRT (66 Gy)    | 49          | F18-FDG PET/CT | SUV<sub>max</sub> | NR               | 14           | Stage III | LC:U | HR 1.01     | 0.92–1.11 | 7                |
| Zhang26      | 2011 | SBRT (50 Gy)   | 68          | F18-FDG PET/CT | SUV<sub>max</sub> | Body weight        | 5            | Stage I  | LC:U | HR 3.00     | 1.00–7.9  | 7                |
| Zhang26      | 2011 | SBRT (50 Gy)   | 60          | F18-FDG PET/CT | SUV<sub>max</sub> | Body weight        | 5            | NR       | LC:U | HR 3.30     | 0.9–10.4 | 6                |
| Zhang26      | 2010 | CRT (60–65 Gy)  | 46          | F18-FDG PET/CT | SUV<sub>max</sub> | Body weight        | 9.8          | Stage III | OS:U+M | HR 10.56    | 8.76–12.36 | 6                |
| Vikram Rao36 | 2012 | SBRT (60 Gy)   | 132         | F18-FDG PET/CT | SUV<sub>max</sub> | Body weight        | 5            | Stage I  | OS:U+M | HR 4.4      | 0.5–35   | 7                |

N, number; SUV<sub>max</sub>, maximum standardized uptake value; NSCLC, non–small-cell lung cancer; SBRT, stereotactic body radiotherapy; CRT, conventional radiotherapy; OS, overall survival; LC, local control; NR, not reported; HR, hazard ratio; CI, confidence interval; U, univariate analysis; M, multivariate analysis; F18-FDG PET/CT, 18F-fluorodeoxyglucose positron emission tomography/computed tomography.
Post-RT SUV\textsubscript{max} was described in five studies (all five also described Pre-RT SUV\textsubscript{max}). In the three studies (227 patients) that reported OS, two claimed that primary tumor SUV\textsubscript{max} could predict OS for RT. In the four studies (391 patients) that reported LC, three claimed significant positive predict value on LC for RT.

Tumor stage and RT regimen were described in most studies (Table 1). In the analysis of pre-RT SUV\textsubscript{max}, seven studies (54.5\% of the total patients) focused on patients with stage I tumor; all these patients were treated with SBRT, for a total dose of 40 to 70 Gy. In the six remaining studies, the tumor stage was variable: stage I to III (n = 3), stage III (n = 2), stage III to IV (n = 1), and not given (n = 1), and the patients received conventional radiotherapy (CRT) with a total dose of 55 to 77 Gy. In post-RT primary tumor SUV\textsubscript{max}, two studies included patients with stage III tumor, whereas the remaining three reports focused on stage I tumor and SBRT.

In all 13 studies included in the meta-analysis, all patients had fasted for at least 6 hours before PET/CT scanning and had a measured blood sugar level approximately 130 to 2000 mg/dl at the time of injection. The threshold level was 150 mg/dl\textsuperscript{24–26,30,34} in five studies, 200 mg/dl\textsuperscript{22,33,36} in one, 175 mg/dl\textsuperscript{31} in one, and not given in the other three publications\textsuperscript{25,32,35}. All the studies obtained emission and transmission scans 60 minutes after the injection of 18F-FDG; however, the dose of 18F-FDG varied across the studies: 5 MBq/kg in three studies\textsuperscript{22,35,36}, 10 to 20 mCi in four\textsuperscript{26,33,34,37}, 10 to 15 mCi in three\textsuperscript{25,31,32}, and 3 to 3.5 MBq/kg in the remaining three studies, respectively. Primary tumor SUV\textsubscript{max} was normalized by body weight in all studies to minimize the partial volume effect.

“High” primary tumor SUV\textsubscript{max} correlated with the outcome. The cutoff for primary tumor SUV\textsubscript{max} ranged from 5 to 15 and was chosen with varying methods across the studies: four using the median SUV\textsubscript{max} of the study sample, four using receiver-operating characteristic curve analysis, one referring to the validation results from another article, and one determined by log-rank test, and not described in the remaining two articles. Optimal timing of 18F-FDG PET/CT after the treatment also varied considerably: 12 weeks (n = 2), 10 weeks (n = 1), 8 to 24 weeks (n = 1), and not described in the remaining one study\textsuperscript{22}.

**Meta-Analysis**

The analysis was performed separately for pre-RT SUV\textsubscript{max} and post-RT SUV\textsubscript{max}. The OS and LC data of both groups were analyzed. Eight studies reported pre-RT SUV\textsubscript{max} and OS\textsuperscript{25,30,32,33–37}; seven reported pre-RT SUV\textsubscript{max} and LC\textsuperscript{22,25,26,30,32}; three reported post-RT SUV\textsubscript{max} and OS\textsuperscript{25,32,36}; and four studies reported post-RT SUV\textsubscript{max} and LC\textsuperscript{22,25,26,36}. Pooled HRs was then calculated for all groups.

Higher pre-RT SUV\textsubscript{max} was correlated with shorter OS (pooled HR, 1.69; 95\% CI, 1.82–2.42). The heterogeneity was significant ($I^2$ statistic = 99\%, $P_{\text{hetogeneity}} = 0.000$). A forest plot attributed most of the heterogeneity to one study\textsuperscript{32}. Reanalyzing the data after exclusion of this article ($I^2$ statistic = 11.9\%, $P_{\text{hetogeneity}} = 0.339$) using a fixed effects model reduced the HR (fixed model) to 1.05 (95\% CI, 1.02–1.08) (Fig. 2A). Sensitivity analysis (by excluding studies with or below six stars) revealed a combined HR at 1.05 (95\% CI, 1.02–1.09) without heterogeneity ($I^2$ statistic = $25.2\%$, $P_{\text{hetogeneity}} = 0.245$), indicating that the sensitivity is low and the result is more robust and credible.
The pooled HR estimate for LC of the six studies using a random-effects model ($I^2$ statistic = 77.8%, $P_{heterogeneity} = 0.000$) was 1.26 (95% CI, 1.05–1.52) (Fig. 2B). The combined HR was 1.24 (95% CI, 1.04–1.49) in a sensitivity analysis ($I^2$ statistic = 79.5%, $P_{heterogeneity} = 0.0255$). Post-RT SUV max also correlated with OS and LC. For OS, the pooled HR was 2.47 (95% CI, 0.58–13.03; $I^2$ statistic = 99.3%, $P_{heterogeneity} = 0.000$). Excluding the same study excluded in the post-RT/OS association, the HR was reduced to 1.32 (95% CI, 1.15–1.51) with well homogeneity ($I^2$ statistic = 0.0%, $P_{heterogeneity} = 0.670$) (Fig. 2C). The pooled HR estimate using a random effects model for LC was 2.01 (95% CI, 1.16–3.46) (Fig. 2D). Again, there was considerable heterogeneity ($I^2$ statistic = 70.6%, $P_{heterogeneity} = 0.017$). A sensitivity analysis was assessed after excluding studies with six stars and excessive cutoff value (cutoff = 14). The combined HR (HR, 2.19; 95% CI, 1.34–3.60 and HR, 2.32; 95% CI, 1.47–3.68) indicates that the sensitivity is low and the result is robust and credible.

The studies were stratified into two groups: SBRT and CRT. In pre-SBRT primary tumor SUV max group, the subjects were stage I patients, and high pre-SBRT SUV max was not significantly associated with poor OS (HR, 1.10; 95% CI, 0.91–1.31) with modest homogeneity across the four included studies ($I^2$ statistic = 49.3%, $P_{heterogeneity} = 0.245$) (Fig. 3A). High pre-SBRT SUV max also correlated to unfavorable LC (HR, 1.28; 95% CI, 1.02–1.60). Eliminating heterogeneity ($I^2$ statistic = 63.4%, $P_{heterogeneity} = 0.018$) by excluding a study that included T1-4N0M0 tumors reduced the HR estimate for LC to 1.11 (95% CI, 1.06–1.18; $I^2$ statistic = 28.3%, $P_{heterogeneity} = 0.242$) (Fig. 3B). The post-SBRT SUV max correlated to LC (HR, 2.19; 95% CI, 1.34–3.60; $I^2$ statistic = 37.1%, $P_{heterogeneity} = 0.204$) (Fig. 3C), with limited data that prevented analysis of OS. For CRT, both high pre-CRT and post-CRT SUV max correlated to poor OS (Table 2).

**Publication Bias**

Publication bias was assessed by Begg’s and Egger’s test. Begg’s test did not find overt publication bias. Formal evaluation using Egger’s test also failed to identify significant publication bias in the analysis of pre-RT SUV max versus OS ($p = 0.317$), and post-RT SUV max versus LC ($p = 0.916$).
Similarly, there was no evidence for significant publication bias in pre-SBRT SUV\textsubscript{max} versus OS ($p = 0.107$) and in pre-CRT SUV\textsubscript{max} versus OS ($p = 0.139$). The results with heterogeneity adjusted are listed in Table 2.

**DISCUSSION**

During the past decade, the role of $^{18}$F-FDG PET/CT has become increasingly important to the patients staging and the radiation treatment planning process in NSCLCs. It has...
been widely reported that SUV\textsubscript{max} of the primary tumor in the \textsuperscript{18}F-FDG PET/CT analysis has potential prognostic use among differently staged and treated populations.\textsuperscript{22,37,39} For patients with resectable NSCLC, a meta-analysis of 13 studies showed that primary tumor SUV\textsubscript{max} has significant prognostic value on patient survival.\textsuperscript{39} Some previous studies suggested an association of high SUV\textsubscript{max} before RT with poor LC\textsuperscript{22} and OS,\textsuperscript{34} but such findings were not replicated by others.\textsuperscript{30} The results of the correct study confirmed a significant correlation of high level of both pre-RT and post-RT SUV\textsubscript{max} with the increased risk of death and local recurrence. Stratified analysis (SBRT versus conventional radiation) also confirmed the prognostic value of primary tumor SUV\textsubscript{max} regardless of the type of the treatment. These results are generally consistent with a previous study;\textsuperscript{24} and particularly so for stage I NSCLC patients treated with SBRT. Whether SUV\textsubscript{max} is a prognostic factor of the outcome in NSCLC patients receiving RT regardless of stage and performance status requires further evaluation.

In the analysis of pre-RT versus OS, most of the heterogeneity could be attributed to one study performed in 46 Chinese patients with stage III NSCLC.\textsuperscript{32} This heterogeneity may be explained by the different methods used to estimate the results and the different threshold used. For example, the method used by the excluded study\textsuperscript{32} to estimate the results was logistic regression model. The analysis of post-RT with OS also had significant heterogeneity (because of the same study). Excluding the prediction value of primary tumor SUV\textsubscript{max} for OS turned into significant (HR, 1.32; 95% CI, 1.15–1.51) from insignificant (HR, 2.47; 95% CI, 0.58–13.03) and demonstrated a poorer OS with high SUV\textsubscript{max}. It is noteworthy, however, that only two studies with 181 patients were included in meta-analysis with acceptable heterogeneity. The results, therefore, must be validated by additional studies. Varying cutoff levels, different scanning equipment, and fractionated dose schemes also contributed to the heterogeneity. Patients in all studies, including the SBRT subgroup analysis, had stage I NSCLC. As a result, the association of high pre-SBRT SUV\textsubscript{max} with unfavorable OS and LC is not clear in patients with more advanced NSCLC. Also, the prognostic value of post-SBRT SUV\textsubscript{max} on OS could not be confirmed in this meta-analysis because of the insufficient available data. A similar situation seems to be true of CRT as well: analysis of all five CRT studies using a random-effects model failed to confirm an association between the pre-CRT or post-CRT SUV\textsubscript{max} and OS/LC; but reducing heterogeneity by excluding the study from China\textsuperscript{32} revealed significant association.

In addition to the absolute value of pre-RT or post-RT SUV\textsubscript{max}, the change of dual time primary tumor SUV\textsubscript{max} also correlated with patient outcome after RT. A study by Clarke et al.\textsuperscript{22} found significantly higher rate of distant failure in patients with a post-SBRT SUV\textsubscript{max} of 2 or more and a reduction of less than 2.55. Another study\textsuperscript{25} also reported the greater decrease in primary tumor SUV\textsubscript{max} that had the highest SUV\textsubscript{max} at diagnosis, the longer OS and disease-free survival for RT. The Satoh study\textsuperscript{30} also suggested that, in comparison with pre-SBRT SUV\textsubscript{max}, high retention index and reduced ratio of SUV\textsubscript{max} had better prognostic value (HR, 47.546; \(p = 0.026\)). The value of the change in dual time points FDG-PET/CT as a prognostic factor for outcome in NSCLC patients receiving RT needs to be further studied, with attention to the method of calculating this change and the cutoff value.

### TABLE 2. Meta-Analysis after Correcting Heterogeneity

| Group | Studies (N) | Q test \(p\) Value | Model Selected | HR (95% CI) \(p\) Value | \(p\) Value |
|-------|-------------|---------------------|----------------|--------------------------|-----------|
| ALL   |             |                     |                |                          |           |
| OS    |             |                     |                |                          |           |
| Pre-RT | 7           | 0.339               | Fixed          | 1.05 (1.02–1.08)         | 0.001     | 0.117    |
| Post-RT | 2           | 0.670               | Fixed          | 1.32 (1.15–1.51)         | 0.000     | —        |
| LC    |             |                     |                |                          |           |
| Pre-RT | 8           | 0.000               | Random         | 1.26 (1.05–1.52)         | 0.012     | 0.017    |
| Post-RT | 5           | 0.024               | Random         | 2.01 (1.16–3.46)         | 0.012     | 0.002    |
| SBRT  |             |                     |                |                          |           |
| OS    |             |                     |                |                          |           |
| Pre-SBRT | 4         | 0.116               | Fixed          | 1.10 (0.91–1.31)         | 0.326     | 0.107    |
| Post-SBRT | 3         | 0.204               | Fixed          | 2.19 (1.34–3.60)         | 0.002     | 0.015    |
| CRT   |             |                     |                |                          |           |
| OS    |             |                     |                |                          |           |
| Pre-CRT | 3           | 0.709               | Fixed          | 1.05 (1.02–1.08)         | 0.001     | 0.777    |
| Post-CRT | 2           | 0.670               | Fixed          | 1.32 (1.15–1.51)         | 0.000     | —        |
| LC    |             |                     |                |                          |           |
| Pre-CRT | 2           | 0.000               | Random         | 2.44 (0.39–15.45)        | 0.343     | —        |
| Post-CRT | 1           | —                   | Random         | 1.19 (1.07–1.33)         | 0.002     | —        |

HR, hazard ratio; CI, confidence interval; OS, overall survival; RT, radiation therapy; LC, local control; SBRT, stereotactic body radiotherapy; CRT, conventional radiotherapy.
The number of the studies, as well as the number of the patients, included in this meta-analysis is relatively small. Also, the data in some of the included studies were analyzed using univariate analysis. As a result, the nature of the observed association is obscure. Another fact is that most of the data were derived from patients with stage I NSCLC. As a result, whether the observed association could be extrapolated to patients with more advanced NSCLC is not certain. Therefore, more high-quality studies with sufficient information needs to be performed, and it should lead to a more significant meta-analysis.

In summary, the current meta-analysis confirmed an association of high pre-RT and post-RT SUVmax of primary tumor with poor outcome in NSCLC patients receiving RT. Such an association seems to be particularly strong for patients with stage I NSCLC receiving SBRT. And it supports further and high-quality investigations of SUVmax on ¹⁸F-FDG PET/CT for predicting poor outcome in NSCLC patients receiving RT.

## REFERENCES

1. Rebecca S, Deepa N, Ahmedin J. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10–29.
2. Verellen D, De Ridder M, Linhout N, Tournel K, Soete G, Storme G. Innovations in image-guided radiotherapy. Nat Rev Cancer 2007;7:949–960.
3. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710–1717.
4. Beitler JJ, Badine EA, El-Sayah D, et al. Stereotactic body radiation therapy for nonmetastatic lung cancer: an analysis of 75 patients treated over 5 years. Int J Radiat Oncol Biol Phys 2006;65:100–106.
5. Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J, Goldstraw P; International Staging Committee and Participating Institutions. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 2009;4:792–801.
6. Jeremić B, Milićević B, Dagović A, Acimović L, Milisavljević S. Pretreatment prognostic factors in patients with early-stage (I/II) non-small-cell lung cancer treated with hyperfractionated radiation therapy alone. Int J Radiat Oncol Biol Phys 2006;65:1112–1119.
7. Rades D, Setter C, Dahl O, Schild SE, Noack F. Fibroblast growth factor—2: a predictor of outcome for patients irradiated for stage II-III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2012;82:442–447.
8. Langendijk H, Thunnissen E, Arends JW, et al. Cell proliferation and apoptosis in stage III inoperable non-small cell lung carcinoma treated by radiotherapy. Radiother Oncol 2000;56:197–207.
9. Choi N, Baumann M, Flentjie M, et al. Predictive factors in radiotherapy for non-small cell lung cancer: present status. Lung Cancer 2003;31:43–56.
10. Mac Manus MP, Hicks RJ, Matthews JP, et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2003;21:1285–1292.
11. Yu JM, Chen SQ. [Advances in research on biological target volume and conformal intensity-modulated radiotherapy]. Zhonghua Zhong Liu Za Zhi 2006;28:801–803.
12. Massacci M, Calcagni ML, Spitzili MG, et al. ¹⁸F-FDG PET-CT during chemo-radiotherapy in patients with non-small cell lung cancer: the early metabolic response correlates with the delivered radiation dose. Int J Radiat Oncol Biol Phys 2012;7:106.
13. Aerts HJ, van Baardwijk AA, Petit SF, et al. Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (¹⁸)Fluorodeoxyglucose-PET/CT scan. Radiother Oncol 2009;91:386–392.
14. Mankoff DA, Bellon JR. Positron-emission tomographic imaging of cancer: glucose metabolism and beyond. Semin Radiat Oncol 2001;11:16–27.
15. Erasmus JJ, Rohren E, Swisher SG. Prognosis and reevaluation of lung cancer by positron emission tomography imaging. Proc Am Thorac Soc 2009;6:171–179.
16. Malone JP, Gerberi MA, Vasireddy S, et al. Early prediction of response to chemoradiotherapy for head and neck cancer: reliability of restaging with combined positron emission tomography and computed tomography. Arch Otolaryngol Head Neck Surg 2009;135:1119–1125.

### Table 3. Newcastle–Ottawa Quality Assessment Scale

| Selection | (1) Representativeness of the exposed cohort |
|-----------|--------------------------------------------|
|           | (a) Truly representative of the average “NSCLC patient receiving radiotherapy” in the community (one star) |
|           | (b) Somewhat representative of the average “NSCLC patient receiving radiotherapy” in the community (one star) |
|           | (c) Selected group of users (e.g., nurses, volunteers) |
|           | (d) No description of the derivation of the cohort |
| (2) Selection of the nonexposed cohort | (a) Drawn from the same community as the exposed cohort (one star) |
|           | (b) Drawn from a different source |
|           | (c) No description of the derivation of the nonexposed cohort |
| (3) Ascertainment of exposure (proof of NSCLC and primary tumor SUVmax measurement) | (a) Secure record (e.g., surgical records) (one star) |
|           | (b) Structured interview (one star) |
|           | (c) Written self-report |
|           | (d) No description |
| (4) Demonstration that outcome of interest was not present at start of study | (a) Yes (one star) |
|           | (b) No |

| Comparability | (1) Comparability of cohorts on the basis of the design or analysis |
|---------------|-------------------------------------------------------------------|
|               | (a) Study controls for “the level of primary tumor SUVmax” (one star) |
|               | (b) Study controls for any additional factor (one star) (age, stage, grade, etc.) |

## Outcome

| (1) Assessment of outcome (death or local recurrence) | (a) Independent blind assessment (one star) |
|-----------------------------------------------------|--------------------------------------------|
|                                                     | (b) Record linkage (one star) |
|                                                     | (c) Self-report |
|                                                     | (d) No description |
| (2) Was follow-up long enough for outcomes to occur? (death or local recurrence) | (a) Yes (“2 years”) (one star) |
|                                                      | (b) No |
| (3) Adequacy of follow-up of cohorts | (a) Complete follow-up—all subjects accounted for (one star) |
|                                                     | (b) Subjects lost to follow-up unlikely to introduce bias—small number lost “(25%)” or description provided of those lost (one star) |
|                                                     | (c) Follow-up rate “<75%” and no description of those lost |
|                                                     | (d) No statement |

* A study can be awarded a maximum of one star for each numbered item within the Selection and Outcome categories. A maximum of two stars can be given for Comparability. Underlined and quoted phrases are provided in the scale to allow for adjustment to particular studies. Italicized phrases indicate our interpretation of the question relevant to this study.

NSCLC, non–small-cell lung cancer; SUVmax, maximum standardized uptake value.
17. Meignan M, Itti E, Gallamini A, Haioun C, et al. Interim \(^{18}\text{F}\)-fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma: qualitative or quantitative interpretation—where do we stand? *Leuk Lymphoma* 2009;50:1753–1756.

18. Specht JM, Kurland BF, Montgomery SK, et al. Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer. *Clin Cancer Res* 2010;16:2803–2810.

19. Ryu JS, Choi NC, Fischman AJ, Lynch TJ, Mathisen DJ. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. *Lung Cancer* 2002;35:179–187.

20. Väntynsel LJ, Vansteenkiste JF, Stroobants SG, et al. The impact of (18) F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. *Radiother Oncol* 2000;55:317–324.

21. Mac Manus MP, Hicks RJ, Matthews JP, et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. *J Clin Oncol* 2003;21:1285–1292.

22. Clarke K, Taremi M, Dahele M, et al. Stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC): is FDG-PET a predictor of outcome? *Radiother Oncol* 2012;104:62–66.

23. Takeda A, Yokosuka N, Ohashi T, et al. The maximum standardized uptake value (SUV\(_{\text{max}}\)) on FDG-PET is a strong predictor of local recurrence for localized non-small-cell lung cancer after stereotactic body radiotherapy (SBRT). *Radiother Oncol* 2011;101:291–297.

24. Sasaki R, Komaki R, Macapinlac H, et al. \(^{18}\text{F}\)-fluorodeoxyglucose positron emission tomography predicts outcome of non-small-cell lung cancer. *J Clin Oncol* 2005;23:1136–1143.

25. Lopez Guerra JL, Gladish G, Komaki R, Gomez D, Zhuang Y, Liao Z. Large decreases in standardized uptake values after definitive radiation are associated with better survival of patients with locally advanced non-small cell lung cancer. *J Nucl Med* 2012;53:225–233.

26. Zhang X, Liu H, Balter P, et al. Positron emission tomography for assessing local failure after stereotactic body radiotherapy for non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2012;83:1558–1565.

27. Wells GA, Brodsky L, O’Connell D, et al. An Evaluation of the Newcastle Ottawa Scale: An Assessment Tool for Evaluating the Quality of on-Randomized Studies. In XI Cochrane Colloquium, Vol. O-63. Barcelona: XI International Cochrane Colloquium Book of Abstracts, 2003. p 26.

28. Dinnes J, Deeks J, Kirby J, Roderick P. A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy. *Health Technol Assess* 2005;9:1–113, iii.

29. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. *Contemp Clin Trials* 2007;28:105–114.

30. Satoh Y, Nambu A, Onishi H, et al. Value of dual time point F-18 FDG-PET/CT imaging for the evaluation of prognosis and risk factors for recurrence in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy. *Eur J Radiol* 2012;81:3530–3534.

31. Lee DS, Kim YS, Yoo IeR, et al. Long-term clinical experience of high-dose ablative lung radiotherapy: high pre-treatment \(^{18}\text{F}\)-fluorodeoxyglucose-positron emission tomography maximal standardized uptake value of the primary tumor adversely affects treatment outcome. *Lung Cancer* 2013;80:172–178.

32. Zhang HQ, Yu JM, Meng X, Yue JB, Feng R, Ma L. [Prognostic value of \(^{18}\text{F}\)-fluorodeoxyglucose uptake in patients with non-small cell lung cancer treated by concurrent chemoradiotherapy]. *Zhonghua Zhong Liu Za Zhi* 2010;32:603–606.

33. Yan H, Wang R, Zhao F, et al. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy. *Acta Radiol* 2011;52:646–650.

34. Chang JY, Liu H, Balter P, et al. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer. *Radiat Oncol* 2012;7:152.

35. Borst GR, Belderbos JS, Boelhaar R, et al. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. *Eur J Cancer* 2005;41:1533–1541.

36. Bollinheni VR, Widder J, Pruijm J, Langendijk JA, Wiegman EM. Residual \(^{18}\text{F}\)-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control. *Int J Radiat Oncol Biol Phys* 2012;83:e551–e555.

37. Burdick MJ, Stephens KL, Reddy CA, Djenil T, Srinivas SM, Videtic GM. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy. *Int J Radiat Oncol Biol Phys* 2010;78:1033–1039.

38. Tierney JF, Stewart LA, Gershik D. Practical methods for incorporating summary time-to-event data into meta-analysis. *Trials* 2007;7:8–16.

39. Berghmans T, Dussart M, Paemans M, et al; European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. Primary tumor standardized uptake value (SUV\(_{\text{max}}\)) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. *J Thorac Oncol* 2008;3:6–12.